



GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

REGD. OFFICE & FACTORY: 69/C GIDC INDUSTRIAL ESTATE,
VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA

TEL: 0260-2430027 / 2400639

E-mail: hrm@gtbl.in.net

GTBL/BSE/NSE/2026-27/16

22nd May, 2026

**Corporate Relationship Department
BSE Limited**

Floor 25, Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code – 506879

**Listing Department
National Stock Exchange of India Limited**

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400051
Symbol: GUJTHEM

Dear Sir / Madam,

Sub: Investor Presentation

In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), we submit herewith the Investors' Presentation of the Gujarat Themis Biosyn Limited ("the Company") for acquisition of 100% equity shareholding in MicroBiopharm Japan Co., Ltd. ("MBJ"), Japan, through Themis Biosyn Japan Limited, a wholly owned Subsidiary incorporated in Japan.

Further, a copy of the same is also available on the website of the Company, viz., www.gtbl.in

Kindly take the same on record and acknowledge receipt of the same.

Thanking you,

Yours faithfully,

For **Gujarat Themis Biosyn Limited**

Dinesh S. Patel
Chairman & Director
DIN: 00033273



Gujarat Themis Biosyn Limited

to Acquire MicroBiopharm Japan Co., Ltd.

Accelerating GTBL's Transition to Fermentation-based Globally Integrated CDMO

Disclaimer



This presentation has been prepared by Gujarat Themis Biosyn Limited ("GTBL") solely for informational purposes in connection with the proposed acquisition of MicroBiopharm Japan Co., Ltd. ("MBJ"). This document is strictly confidential and is intended solely for the use of the individual or entity to whom it is addressed.

This presentation contains forward-looking statements that involve risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied in such statements. GTBL does not undertake any obligation to publicly update or revise any forward-looking statement.

The information contained herein is based on publicly available data and internal estimates. No representation or warranty, express or implied, is made as to the accuracy, completeness, or fairness of the information presented. Recipients should not rely on this document as the basis for any investment decision.

The transaction described herein is subject to customary regulatory approvals and closing formalities. There can be no assurance that the transaction will be completed on the terms described or at all.

Table of Contents



Transaction Details



About MicroBiopharm Japan



Strategic Rationale



Synergies & Value Creation

01 | Transaction Details



Structure

Acquisition of 100% equity in MicroBiopharm Japan Co., Ltd. (MBJ) via a wholly owned SPV incorporated in Japan

Seller

Funds managed or advised by T Capital Partners Co., Ltd. (Japan-based Private Equity Fund)

Consideration

JPY 21.5 Billion/Bn (~INR 1,300 Crore/Cr); funded through an optimal mix of debt and equity. Transaction expected to be EPS accretive

Management

Existing MBJ management team to continue leading operations

Expected Close

Q2 FY2027, subject to customary regulatory approvals and closing formalities



60+

Years of Experience


3 Plants

GMP-Compliant, with FDA & PMDA
Approval Track Record

JPY 9.5 Bn
(INR ~570 Cr)

FY 26E Revenue

Business Mix



KEY STRENGTHS

Fermentation

Bacterial culture, microbial fermentation, large scale fermentation, Precision Fermentation

Customer Relationships

Servicing Top 6 customers for over two decades*
40% revenue from outside of Japan

Novel Technology Platforms

Plasmid DNA, ADC Conjugation , Strain & Process Optimization and P450 enzyme library

Management

Experienced Management with strong scientific background and association with academia

Note : The company follows a financial year cycle spanning April to March

*as on FY25



Accelerates GTBL's Transition Towards Fermentation-based Globally Integrated CDMO

Precision Fermentation & Molecular Engineering

Entry into precision fermentation through MBJ's proprietary P450 enzyme library (hydroxylation), complementing GTBL's existing fermentation strengths

Proprietary Products : APIs

Supply of API/Intermediates for Oncology, Immunosuppressants, Peptides and Antibiotics to leading global pharma companies including Big Pharma

Advanced Biologics & Novel Modalities

Access to Plasmid DNA, ADC conjugation, and recombinant protein technologies

Scalable, Regulated Manufacturing Footprint


Three GMP-compliant sites with strong FDA and PMDA inspection track records, enabling expanded access to regulated global markets

Diversified Global Revenue Base

~40% of MBJ revenues from outside Japan; long-standing relationships with blue-chip pharma customers across Asia, Europe & North America

India Cost Advantage for Margin Expansion

Opportunity to leverage GTBL's India manufacturing scale to improve cost competitiveness and drive margin expansion on high-value products



Enhanced Fermentation & Precision Biotech Capabilities

Strengthens fermentation capabilities and enables entry into precision fermentation via proprietary P450 enzyme libraries — reducing reliance on traditional chemical routes




Expanded Product Portfolio & Therapeutic Coverage

Broadens GTBL's API and intermediates portfolio across oncology, immunosuppressants, and peptides — enhancing product depth and revenue diversification



CDMO Platform

Provides access to a fully integrated CDMO platform spanning discovery, development, and commercial manufacturing, enabling long-term customer partnerships and recurring revenues



Entry into Advanced Biologics & Novel Modalities

Unlocks biologics, plasmid DNA, and ADC conjugation capabilities — positioning the platform in high-growth, innovation-led pharmaceutical segments



Access to Established Big Pharma Relationships

Leverages MBJ's long-standing partnerships with global pharma leaders — enabling cross-selling, higher wallet share, and accelerated market penetration



Contact Information

Gujarat Themis Biosyn Limited

Mr. Krupesh Patel

Chief Financial Officer

Email: krupesh.patel@themismedicare.com

Web: www.gtbl.in

Investor Relations — Adfactors PR

Mr. Rahul Trivedi / Ms. Saloni Nagvekar

Investor Relations

Email: rahul.trivedi@adfactorspr.com
saloni.nagvekar@adfactorspr.com

Web: www.adfactorspr.com



Thank You

Building Fermentation-based Globally Integrated CDMO

Gujarat Themis Biosyn Limited | www.gtbi.in